Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

News

  • Home
  •  
  • News



  • Most Read
  • Latest Comments
  • Starpharma gains regulatory approval in Malaysia for nasal spray to build momentum in Asia
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Starpharma gains regulatory approval in Malaysia for nasal spray to build momentum in Asia
    • News

    Smart pain assessment app now used by more than half of Australia’s residential aged care providers
    Public
  • Starpharma gains regulatory approval in Malaysia for nasal spray to build momentum in Asia
    • News

    Fledgling fintech hopes millennials put their Douugh into micro-investing ‘super’ app
    Public
  • Starpharma gains regulatory approval in Malaysia for nasal spray to build momentum in Asia
    • News

    🎵 The knee bone’s connected to the… collagen rope device (?!)
    Public
  • Starpharma gains regulatory approval in Malaysia for nasal spray to build momentum in Asia
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial
    • Review
    • September 1, 2022

Latest Articles

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Mayne Pharma settles shareholder class action for $38M with no admission of guilt
    Mayne Pharma settles shareholder class action for $38M with no admission of guilt
    • News

  • Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    • News

  • Firebrick’s nasal hygiene spray launched in the US without FDA approvals
    Firebrick’s nasal hygiene spray launched in the US without FDA approvals
    • News

  • Amplia reports results from initial clinical trials of pancreatic cancer drug
    Amplia reports results from initial clinical trials of pancreatic cancer drug
    • News

  • Alterity Therapeutics moves neuroprotective drug to Phase 2 trials
    • News

    Alterity Therapeutics moves neuroprotective drug to Phase 2 trials

    Seven to ten years. That’s how long someone diagnosed with multiple system atrophy (MSA) has to live from when symptoms first appear. The progressive disease results in the gradual functional decline of the body’s involuntary functions such as blood pressure, breathing, bladder function and motor control. Often confused with Parkinson’s which is characterised by the

    Read More
    Public
  • Bubs to the rescue as special operation gets underway
    • News

    Bubs to the rescue as special operation gets underway

    Shareholders of Bubs Australia (ASX: BUB) reveled in every small cap investors’ dream over the weekend – a direct shoutout from the President of the United States. And this morning the President issued a follow-up that will renew shareholders’ excitement – it might not quite get the attention of an incendiary ex President Trump tweet,

    Read More
    Public
  • The Cancer Index: Why investing in oncology biotechs is more science than art
    • News

    The Cancer Index: Why investing in oncology biotechs is more science than art

    Despite what it may look like, investing in biotechs is more science than art. The sector holds intrinsically higher risk, but investing in it can be well worth it to those willing to take the plunge. In fact, over the last twenty years biotech firms have outperformed the S&P 500 and both the medtech andRead More
    Public
  • Phase II begins for FirstWave’s cyber defence platform
    • News

    Phase II begins for FirstWave’s cyber defence platform

    Cyber crimes worldwide have been getting worse as the internet gets better, with reports from the national cybersecurity agency in Australia reporting cybercrimes increasing 13% in 2021, with an incident occurring on average every 8 minutes. As new attack methods and vectors, and the use of sophisticated AI evolve, the average business loss from email

    Read More
    Public
  • Forget the details, Mighty Kingdom has just inked a deal with Google
    • News

    Forget the details, Mighty Kingdom has just inked a deal with Google

    Gaming company Mighty Kingdom (ASX: MKL) has partnered with some of the world’s most recognised brands like LEGO, Disney and now Google, with the Company today announcing a new contract. Google will work with Mighty Kingdom for an upcoming technology partnership under a fixed term six month ‘work for hire’ agreement. Any description of the

    Read More
    Public
  • Envirosuite’s machine learning wastewater tech ahead of schedule, accelerates growth
    • News

    Envirosuite’s machine learning wastewater tech ahead of schedule, accelerates growth

    Environmental intelligence company Envirosuite (ASX: EVS) has provided a promising update on its newest product, EVS Water, which has picked up new customers in Australia, Asia , Europe and the US with revenues ahead of originally forecast. The technology is close to achieving its initial goal of $1m in total sales, only one year into

    Read More
    Public
  • Institutional investors back Apiam to accelerate growth amid regional boom
    • News

    Institutional investors back Apiam to accelerate growth amid regional boom

    With it now abundantly clear that Australians who moved away from capital cities at the start of the pandemic have zero intention of returning to traffic jams and shoebox apartments, institutional investors have seen the light by backing regional vet operator Apiam Animal Health (ASX: AHX) to deliver on their ambitious regional expansion strategy.  Over

    Read More
    Public
  • Now you see me, ClearVue and Nodis powering glass for US Air Force
    • News

    Now you see me, ClearVue and Nodis powering glass for US Air Force

    ClearVue Technologies Ltd (ASX: CPV) and smart glass company Nodis Pte Ltd have signed a collaboration agreement to engineer an electronically controlled window solution for the US Air Force. The Companies have undertaken a first phase evaluation for the US Air Force at Tyndall Air Force Base in Florida trialling Nodis’ dynamic switchable glazing powered

    Read More
    Public
  • Cynata to tackle common transplant side effect with lead drug CYP-001
    • News

    Cynata to tackle common transplant side effect with lead drug CYP-001

    The first successful organ donation occurred in 1954 where a living donor gave a kidney to his identical twin. Since then, organ donation has become a routine practice with over 25,000 transplants conducted per year in US hospitals. Transplantation is far from simple, with an immense amount of preparation and aftercare required for recipients. A

    Read More
    Public
  • The key to happiness lies in your gut… No, really, just ask Microba
    • News

    The key to happiness lies in your gut… No, really, just ask Microba

    It’s no wonder that the health and wellness industry is worth over $4 trillion when you look at my bank statement. Perpetually on a health kick, I have been known to spend on gym memberships, protein powders, supplements, activewear and runners, and I’m not alone with many Aussies spending a serious chunk of cash on

    Read More
    Public
  • «
  • ‹
  • 177
  • 178
  • 179
  • 180
  • 181
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.